VistaGen Therapeutics logo
VistaGen Therapeutics VTGN
$ 0.16 -15.79%
report update icon

Quarterly report 2027-Q2
added 11-13-2026

VistaGen Therapeutics Long-Term Debt | VTGN

Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.

Main characteristics:
  • Term exceeds 12 months
  • Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
  • Repaid through regular payments (interest and/or principal) over several years
Why long-term debt is needed:
  • Investment in development
    Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital.
  • Smoothing of cash flows
    A long-term payment schedule facilitates budget planning and reduces short-term financial risks.
  • Optimization of capital structure
    A combination of equity and borrowed capital can reduce the average cost of business financing.

A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.

If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.

It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.

Examples of long-term debt:
  • Mortgage loans for property purchases
  • Corporate bonds issued by a company to raise capital
  • Project financing — long-term loans for building or expanding production facilities
  • Leasing obligations for equipment or transport

Annual Long-Term Debt VistaGen Therapeutics

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999
249 K 948 K 1.57 M 7.4 K - 3.35 M 3 K 6.3 K - - 58.8 K 332 K 2.06 M 4.62 M 2.67 M - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
4.62 M 3 K 1.32 M

Quarterly Long-Term Debt VistaGen Therapeutics

2027-Q2 2027-Q1 2026-Q4 2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
- 63 K 249 K 431 K 610 K 783 K 948 K 1.11 M 1.27 M 1.42 M 1.57 M 1.71 M 1.85 M 7 K 2.12 M 6.5 K 7 K 7.4 K 2.61 M 2.25 M 8.7 K 2.49 M 2.72 M 3.14 M 3.25 M 3.25 M 3.45 M 87.3 K 125 K 3.96 M 3.8 M 3.88 M 3.96 M 6.3 K - - - - - - - - 27.2 K - - 27.2 K 1.51 M 31.4 K 1.04 M 35.6 K 1.93 M - - 1.8 M - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
3.96 M 6.3 K 1.45 M

Long-Term Debt of other stocks in the Biotechnology industry

Issuer Long-Term Debt Price % 24h Market Cap Country
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
175 M - - - russiaRussia
Lyra Therapeutics Lyra Therapeutics
LYRA
25.4 M - - $ 24.9 M usaUSA
Brickell Biotech Brickell Biotech
BBI
146 K - -5.38 % $ 6.06 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
2.39 M - - $ 8.42 M usaUSA
ESSA Pharma ESSA Pharma
EPIX
205 K - - $ 8.86 M canadaCanada
Generation Bio Co. Generation Bio Co.
GBIO
80.6 M - - $ 344 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
328 K - - $ 25.3 M usaUSA
Merus N.V. Merus N.V.
MRUS
8.21 M - - $ 5.78 B niderlandNiderland
RAPT Therapeutics RAPT Therapeutics
RAPT
2.07 M - - $ 2.36 B usaUSA
Annexon Annexon
ANNX
23.3 M $ 3.11 -8.94 % $ 482 M usaUSA
Acasti Pharma Acasti Pharma
ACST
410 K - 4.01 % $ 150 M canadaCanada
Aptose Biosciences Aptose Biosciences
APTO
193 K - -45.71 % $ 1.2 M canadaCanada
Galapagos NV Galapagos NV
GLPG
5.19 M - - $ 1.83 B belgiumBelgium
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
2 K - -4.36 % $ 27 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
2.03 M - -52.27 % $ 4.45 M usaUSA
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.
GLMD
44 K $ 4.63 21.05 % $ 20 M israelIsrael
Achieve Life Sciences Achieve Life Sciences
ACHV
11.2 M $ 6.78 0.89 % $ 296 M usaUSA
Leap Therapeutics Leap Therapeutics
LPTX
262 K - 368.57 % $ 41.9 M usaUSA
Lumos Pharma Lumos Pharma
LUMO
303 K - - $ 35.3 M usaUSA
Axcella Health Axcella Health
AXLA
25.1 M - -16.42 % $ 249 M usaUSA
Metacrine Metacrine
MTCR
13.3 M - - $ 24.2 M usaUSA
Zealand Pharma A/S Zealand Pharma A/S
ZEAL
125 M - 0.52 % $ 821 M danmarkDanmark
Myovant Sciences Ltd. Myovant Sciences Ltd.
MYOV
7.04 M - -0.04 % $ 2.62 B usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
203 K - -74.18 % $ 955 K usaUSA
Idera Pharmaceuticals Idera Pharmaceuticals
IDRA
326 K - -23.04 % $ 26.6 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
529 K - - $ 3.67 B usaUSA
Verona Pharma plc Verona Pharma plc
VRNA
120 M - - $ 69.7 B britainBritain
Atreca Atreca
BCEL
60.3 M - -11.76 % $ 5.79 M usaUSA
Guardion Health Sciences Guardion Health Sciences
GHSI
3.81 K - -0.31 % $ 3.64 M usaUSA
Opiant Pharmaceuticals Opiant Pharmaceuticals
OPNT
673 K - - $ 109 M usaUSA
Akouos Akouos
AKUS
28.3 M - 0.23 % $ 488 M usaUSA
ImmunoGen ImmunoGen
IMGN
11.1 M - - $ 7.92 B usaUSA
Vascular Biogenics Ltd. Vascular Biogenics Ltd.
VBLT
263 K - -8.77 % $ 12.4 M israelIsrael
Cidara Therapeutics Cidara Therapeutics
CDTX
310 K - - $ 1.41 B usaUSA
Iterum Therapeutics Iterum Therapeutics
ITRM
31.2 M - - $ 591 K irlandaIrlanda
Navidea Biopharmaceuticals Navidea Biopharmaceuticals
NAVB
1.31 K - -2.99 % $ 2.47 M usaUSA
Stealth BioTherapeutics Corp Stealth BioTherapeutics Corp
MITO
13.7 M - - $ 23.9 M usaUSA
OncoSec Medical Incorporated OncoSec Medical Incorporated
ONCS
937 K - 31.87 % $ 1.61 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
219 K - -4.8 % $ 255 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
10.8 M - -0.23 % $ 916 M usaUSA
bluebird bio bluebird bio
BLUE
7.8 M - - $ 546 M usaUSA
CASI Pharmaceuticals CASI Pharmaceuticals
CASI
476 K - - $ 35.4 M usaUSA
ContraFect Corporation ContraFect Corporation
CFRX
2.21 M - -5.16 % $ 5.39 M usaUSA
Sigilon Therapeutics Sigilon Therapeutics
SGTX
12 M - - $ 728 M usaUSA